Hepion Pharmaceuticals Inc. (NASDAQ: HEPA): Analyst View Points To Future Growth


After grabbing 12881.0 shares, the institutional investor is now in possession of 12881.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.14% having worth around $52039.0. Moreover, Royal Alliance Associates, Inc. (.. increased its share by 1000.0 to have a control over 1000.0 shares. And Private Advisor Group LLC raised its holdings to 104.0 shares by acquiring 104.0 shares or 0.00% of the stake.

Hepion Pharmaceuticals Inc. (HEPA) concluded trading on 08/27/20 at a closing price of $3.53, with 1.23 million shares of worth about $4.35 million changed hands on the day. Weekly performance of the stock remained negative as price took a plunge of -7.35% during that period and on Thursday the price saw a gain of about 0.86%. Currently the company’s common shares owned by public are about 8.50M shares, out of which, 6.07M shares are available for trading.

A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 2 analysts are covering the HEPA stock and their offered price forecasts bring an average price target of $13.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $14.00 and could fall to a lowest price of $12.00. Analysts also issued an outlook of 2.00 for the Hepion Pharmaceuticals Inc. stock for next 12 months. However, touching the estimated high of $14.00 would mean a gain of 74.79% for the stock.

According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.

DFA US Micro Cap Portfolio, DFA US Targeted Value Portfolio, and Vanguard Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Hepion Pharmaceuticals Inc. DFA US Micro Cap Portfolio is currently holding 11778.0 shares of worth totaling $47583.0. The company recently came buying 9560.0 shares which brought its stake up to 0.13% of the company’s outstanding shares. DFA US Targeted Value Portfolio bought 3400.0 shares, after which its hold over company’s outstanding shares expand to 0.13%, leaving 11338.0 shares with the mutual fund that have a worth of about $45806.0. Vanguard Extended Market Index Fu, after buying 1446.0 shares, have now control over 0.02% of the stake in the company. It holds 0.0 shares of worth $5842.0.

Hepion Pharmaceuticals Inc. (NASDAQ: HEPA) started trading at $3.55, above $0.05 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $3.53, or with a gain of 0.86%. Stock saw a price change of -7.35% in past 5 days and over the past one month there was a price change of -15.95%. Year-to-date (YTD), HEPA shares are showing a performance of -34.14% which increased to 46.47% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.00 but also hit the highest price of $8.35 during that period. While comparing its average daily trading volume of 1.68 million shares, we see that about 1.23 million changed hands on the day. The stock is currently trading -11.06% below its 20-day simple moving average (SMA20), while that difference is down -1.81% for SMA50 and it goes to 3.20% higher than SMA200.

Squarepoint OPS LLC acquired 12881.0 shares of Hepion Pharmaceuticals Inc. having value of about $52039.0. Hepion Pharmaceuticals Inc. (NASDAQ: HEPA) currently have 8.50M outstanding shares and institutions hold larger chunk of about 3.60% of that. Holding of mutual funds in the company is about 0.28% while other institutional holders and individual stake holders have control over 1.28% and 0.01% of the stake respectively.

The stock has a current market capitalization of $31.63M and its 3Y-monthly beta is at 1.90. It has posted earnings per share of -$2.61 in the same period. It has Quick Ratio of 7.00 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HEPA, volatility over the week remained 7.43% while standing at 7.16% over the month.

Analysts are in expectations that Hepion Pharmaceuticals Inc. (HEPA) stock would likely to be making an EPS of -$0.48 in the current quarter, while forecast for next quarter ESPS is -$0.37 and it is -$1.21 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.5 which is -$0.47 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.53 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 93.70% while it is estimated to decrease by -181.00% in next year.

Analysts at 2 brokerage firms have issued recommendations for the Hepion Pharmaceuticals Inc. (HEPA)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 2 Wall Street analysts, 2 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by ROTH Capital on July 20, 2020 offering a Buy rating for the stock and assigned a target price of $14 to it.


Please enter your comment!
Please enter your name here